VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HUMHumana Inc.
$383.84$46.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksHUMFinancials

Humana Inc. (HUM) Financials

30Y historyFree accessUpdated daily

Revenue growth accelerated to 23.5% in 2026Q1, though profitability remains strained by gross margins that have fluctuated between 11.7% and 17.4% over the last ten quarters.

HUM Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue137.2B129.66B117.81B106.44B92.92B83.65B77.19B64.93B56.94B53.8B54.41B54.29B48.5B41.31B39.13B36.83B33.87B30.96B29.05B25.29B21.42B14.42B13.1B12.23B11.26B10.19B10.6B10.21B9.87B8.04B6.79B
Revenue Growth %14.08%10.06%10.68%14.55%11.09%8.37%18.88%14.03%5.84%-1.11%0.21%11.94%17.4%5.59%6.23%8.75%9.39%6.58%14.87%18.09%48.54%10.03%7.18%8.57%10.46%-3.79%3.76%3.5%22.77%18.39%44.36%
Cost of Goods Sold0------------------------------
COGS % of Revenue-------------------------------
Gross Profit19.22B18.85B17.15B18.05B17.23B14.45B15.69B11.19B11.19B7.08B7.77B7.76B7.97B6.69B6.13B5.67B4.76B4.48B4.17B3.66B3.17B0012.23B11.26B10.19B10.6B10.21B9.87B8.04B6.79B
Gross Margin %14.01%14.54%14.55%16.95%18.54%17.27%20.33%17.24%19.65%13.17%14.28%14.3%16.44%16.19%15.65%15.38%14.06%14.46%14.34%14.48%14.8%--100%100%100%100%100%100%100%100%
Gross Profit Growth %-9.94%-4.98%4.72%19.26%-7.91%40.18%0.02%57.95%-8.79%0.04%-2.6%19.2%9.19%8.12%18.93%6.38%7.51%13.76%15.49%---100%8.57%10.46%-3.79%3.76%3.5%22.77%18.39%44.36%
Operating Expenses17.83B17.4B15.52B14.73B13.67B11.03B11.02B7.72B9.12B7.08B7.77B7.76B7.97B6.69B6.13B5.67B4.76B4.48B4.17B3.66B3.17B02B11.89B11.06B10.01B10.48B10.62B9.66B1.14B1.05B
OpEx % of Revenue-13.42%13.17%13.84%14.71%13.19%14.27%11.89%16.01%13.17%14.28%14.3%16.44%16.19%15.65%15.38%14.06%14.46%14.34%14.48%14.8%-15.23%97.25%98.19%98.2%98.92%103.96%97.94%14.14%15.42%
Selling, General & Admin00000000000000000000001.88B1.87B1.78B1.55B1.52B1.47B1.41B1.12B940M
SG&A % of Revenue----------------------14.33%15.27%15.82%15.16%14.39%14.36%14.32%13.89%13.85%
Research & Development0------------------------------
R&D % of Revenue-------------------------------
Other Operating Expenses0------------------------------
Operating Income1.38B1.45B1.63B3.32B3.56B3.42B4.67B3.47B2.07B3.33B1.74B2.35B2.36B2.06B2.06B2.34B2.02B1.71B1.18B1.36B825.23M461.03M439.02M336.21M203.55M183.08M113.99M-404.84M203.08M6.9B5.74B
Operating Margin %1.01%1.12%1.38%3.12%3.84%4.09%6.06%5.34%3.64%6.18%3.2%4.32%4.87%4.99%5.27%6.36%5.96%5.52%4.05%5.37%3.85%3.2%3.35%2.75%1.81%1.8%1.08%-3.96%2.06%85.86%84.58%
Operating Income Growth %--10.69%-50.99%-6.85%4.24%-26.85%34.7%67.31%-37.64%91.04%-25.82%-0.64%14.6%-0.05%-12.03%16.21%18.12%45.18%-13.4%64.58%79%5.01%30.58%65.18%11.18%60.61%128.16%-299.35%-97.06%20.19%39.34%
EBITDA2.19B2.28B2.6B4.24B4.41B4.13B5.29B4.04B2.61B3.81B2.21B2.79B2.81B2.49B2.4B2.65B2.28B1.96B1.4B1.54B973.82M589.89M556.81M462.99M324.28M354.1M267.61M-277.88M331.08M7.01B5.84B
EBITDA Margin %1.59%1.76%2.2%3.98%4.74%4.94%6.85%6.23%4.58%7.08%4.05%5.15%5.8%6.02%6.13%7.19%6.73%6.32%4.81%6.1%4.55%4.09%4.25%3.79%2.88%3.47%2.53%-2.72%3.36%87.21%86.02%
EBITDA Growth %-32.21%-12.25%-38.75%-3.9%6.7%-21.89%30.78%55.1%-31.57%72.76%-21.05%-0.6%13.03%3.62%-9.33%16.1%16.45%40.19%-9.49%58.45%65.09%5.94%20.26%42.78%-8.42%32.32%196.3%-183.93%-95.28%20.02%39.36%
D&A (Non-Cash Add-back)803M824M968M917M845M713M616M575M534M485M465M447M449M426M338M303M263M250.27M220.35M184.81M148.6M128.86M117.79M126.78M120.73M171.02M153.62M126.96M128M108M98M
EBIT2.05B2.08B2.29B3.81B3.96B3.75B4.96B3.71B2.29B4.75B2.21B3.06B2.81B2.49B2.35B2.65B2.12B1.96B1.29B1.54B973.82M461.03M439.02M353.58M220.8M208.38M142.6M-371.45M250.06M20M11M
Net Interest Income-664M-631M-660M-493M-401M-326M-283M-242M-218M-242M-189M-186M-192M-140M-105M-109M-105M-105.84M-80.29M-68.88M-63.14M-39.31M-23.17M-17.37M-17.25M-25.3M-28.61M-33.39M-46.97M-20M-11M
Interest Income0000000000000000000000000000000
Interest Expense664M631M660M493M401M326M283M242M218M242M189M186M192M140M105M109M105M105.84M80.29M68.88M63.14M39.31M23.17M17.37M17.25M25.3M28.61M33.39M46.97M20M11M
Other Income/Expense0------------------------------
Pretax Income1.38B1.45B1.63B3.32B3.56B3.42B4.67B3.47B2.07B4.02B1.55B2.43B2.17B1.92B1.91B2.23B1.75B1.6B992.85M1.29B762.09M421.71M415.85M336.21M203.55M183.08M113.99M-404.84M203.08M00
Pretax Margin %1.01%1.12%1.38%3.12%3.84%4.09%6.06%5.34%3.64%7.47%2.85%4.48%4.47%4.65%4.88%6.07%5.17%5.17%3.42%5.1%3.56%2.92%3.17%2.75%1.81%1.8%1.08%-3.96%2.06%--
Income Tax239M250M413M836M762M485M1.31B763M391M1.57B938M1.16B1.02B690M689M816M650M562.09M345.69M455.62M274.66M113.23M135.84M112.47M67.18M65.91M23.94M-22.42M74M97M6M
Effective Tax Rate %17.27%17.21%25.38%25.18%21.38%14.19%27.96%21.99%18.85%39.1%60.44%47.51%47.14%35.92%36.05%36.51%37.15%35.09%34.82%35.34%36.04%26.85%32.67%33.45%33%36%21%5.54%36.44%--
Net Income1.13B1.19B1.21B2.49B2.81B2.93B3.37B2.71B1.68B2.45B614M1.28B1.15B1.23B1.22B1.42B1.1B1.04B647.15M833.68M487.42M308.48M280.01M223.74M142.75M117.17M90.05M-382.42M128.96M173M12M
Net Margin %0.82%0.92%1.02%2.34%3.02%3.51%4.36%4.17%2.96%4.55%1.13%2.35%2.36%2.98%3.12%3.85%3.24%3.36%2.23%3.3%2.28%2.14%2.14%1.83%1.27%1.15%0.85%-3.74%1.31%2.15%0.18%
Net Income Growth %-33.92%-1.57%-51.51%-11.3%-4.33%-12.89%24.38%60.84%-31.25%298.7%-51.88%11.25%-6.82%0.74%-13.88%29.12%5.71%60.65%-22.37%71.04%58.01%10.17%25.15%56.73%21.83%30.11%123.55%-396.55%-25.46%1341.67%-93.68%
Net Income (Continuing)1.15B1.2B1.21B2.48B2.8B2.93B3.37B2.71B1.68B2.45B614M1.28B1.15B1.23B1.22B1.42B1.1B1.04B647.15M833.68M487.42M308.48M280.01M223.74M142.75M117.17M90.05M-382.42M129M173M12M
Discontinued Operations0000000000000000000000000000000
Minority Interest66M80M70M56M59M23M0000000000000000000000000
EPS (Diluted)9.379.849.9820.0022.0822.6725.3120.1012.1616.814.078.447.367.737.478.466.476.153.834.912.901.871.721.380.830.700.54-2.280.771.050.07
EPS Growth %-33.92%-1.4%-50.1%-9.42%-2.6%-10.43%25.92%65.3%-27.66%313.02%-51.78%14.67%-4.79%3.48%-11.7%30.76%5.2%60.57%-22%69.31%55.08%8.72%24.64%66.27%18.57%29.63%123.68%-396.1%-26.67%1400%-93.97%
EPS (Basic)-9.8710.0120.0922.2022.7925.4720.1912.2416.944.118.547.447.827.578.586.556.213.875.002.971.911.751.410.850.710.54-2.280.771.060.07
Diluted Shares Outstanding120.65M120.83M120.87M124.44M127.09M129.4M133.01M134.73M138.4M145.58M150.92M151.14M155.87M159.15M163.46M167.83M169.8M169.07M168.97M169.82M168.08M164.96M162.8M162.13M171.99M167.39M166.76M167.73M167.48M165.84M165.28M
Basic Shares Outstanding120.33M120.45M120.57M123.87M126.42M128.69M132.2M134.05M137.49M144.49M149.37M149.45M154.19M157.5M161.48M165.41M167.78M167.36M167.17M166.87M164.12M161.51M160.01M158.68M167.95M165.03M166.76M167.73M167.48M163.41M162.53M
Dividend Payout Ratio-36.2%35.71%17.32%13.97%12.07%9.59%10.75%15.75%8.99%28.83%13.48%15%13.65%13.5%5.78%---------------

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

CMS reimbursement rate volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Outpacing Historical Norms

According to the latest quarterly financial data, Humana achieved a 23.5% year-over-year revenue increase in 2026Q1, marking a significant acceleration from the double-digit growth rates observed throughout 2024 and 2025, which suggests a successful scaling of its core Medicare Advantage membership base despite broader industry headwinds.

The recent surge in top-line performance appears to be driven by aggressive member acquisition, though investors should monitor whether this growth is sustainable given the competitive intensity of the Medicare Advantage market. The acceleration warrants further investigation into whether this volume expansion is coming at the expense of long-term pricing power or if it reflects a successful capture of market share from less specialized peers.

Structural Margin Compression Remains Persistent

As reported in recent income statements, Humana's gross margin fluctuated between 11.7% and 17.4% over the last ten quarters, reflecting the inherent volatility of medical loss ratios in a post-pandemic environment where senior utilization of outpatient and orthopedic services has consistently pressured the company's core profitability.

The inability to maintain a stable gross margin suggests that the company's actuarial models may be struggling to keep pace with the current medical cost trend. This margin instability implies that Humana is highly sensitive to external utilization shocks, making its profitability profile appear structurally vulnerable to any unexpected spikes in high-acuity care demand.

Fourth Quarter Seasonal Earnings Volatility

Based on the provided financial history, the fourth quarter of each fiscal year consistently acts as a negative inflection point, with 2024Q4 and 2025Q4 reporting operating losses of $899 million and $1.0 billion respectively, highlighting a recurring seasonal pattern of elevated medical claims and year-end reserve adjustments.

These recurring year-end losses suggest that the company's cost recognition process is heavily back-weighted, potentially masking underlying margin trends during the first three quarters of the year. Analysts should interpret these Q4 results as a critical indicator of the company's true annual medical cost exposure rather than mere seasonal noise.

Sustainability of Medicare Advantage Model

Data from the company's recent filings indicates that the reliance on government-funded programs creates a binary risk profile, where any adverse shift in CMS reimbursement rates or Star Rating methodologies could rapidly erode the thin operating margins that currently characterize the firm's core insurance operations.

Short-term profitability gains may be masking a long-term structural risk where the cost of providing care in a value-based model exceeds the reimbursement growth provided by federal regulators. Investors should remain cautious, as the current reliance on Medicare Advantage leaves little room for error if medical inflation continues to outpace annual premium adjustments.

HUM — Frequently Asked Questions

Quick answers to the most common questions about buying HUM stock.

What was Humana Inc.'s (HUM) revenue in 2025?

For fiscal year 2025, Humana Inc. (HUM) reported total revenue of $129.66B. This represents a 1810.2% increase compared to $6.79B in 1996.

Is Humana Inc. (HUM) profitable?

Humana Inc. (HUM) is profitable, generating $1.19B in net income for the fiscal year ending 2025 with a net profit margin of 0.9%.

What is Humana Inc.'s operating profit margin?

Humana Inc. (HUM) reported an operating income of $1.45B, resulting in an operating profit margin of 1.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Humana Inc.'s gross profit and gross margin?

Humana Inc. (HUM) generated $18.85B in gross profit for the year, representing a gross profit margin of 14.5%. This demonstrates the company's core pricing power and production efficiency.